Most physicians hear about board seats as something that happens to other people, usually after a long career in pharma medical leadership. That pattern is real. It is also incomplete. When a public biotech names a physician director, the press release is a short map of the skills chairs are willing to defend to shareholders.
What happened
On 28 October 2026, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage medical dermatology company, announced that Rob Scott, MD had been appointed to its Board of Directors effective 23 October 2026. Arcutis focuses on chronic inflammatory skin disease and markets ZORYVE across several indications.
CEO Frank Watanabe said Scott had played a central role in bringing important medicines, including dermatology and immunology therapies, to market, and that his development-through-approval experience would matter as the company advances its pipeline. Scott's own comment pointed at ZORYVE adoption, additional indications, a novel biologic in development, and remaining unmet need in chronic skin disease.
The biography is the part physicians should study. Scott previously served as Chief Medical Officer at AbbVie, with responsibility for roughly 40 new molecular entities and about 4,000 team members before retiring in 2020. During that tenure AbbVie achieved more than 14 major regulatory approvals, including Venclexta, Orilissa, Skyrizi and Rinvoq. He created AbbVie's Development Design Center, focused on AI, predictive analytics and big data for trial design. Earlier he was vice president of global development at Amgen, including work that supported Repatha's approval. He served on the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016 and participated fourteen times. Earlier at Pfizer he worked on programmes including Lipitor and Norvasc. He has sat on multiple public and private boards and scientific and strategic advisory boards. He is a Zimbabwean-born physician and a graduate of the University of Cape Town.
What this means for physicians
This appointment will not open an application for every dermatologist. It does show, in public language, what a commercial-stage board was willing to put on the record.
First, the seat is framed around development-to-approval judgement and pipeline risk, not around "being a doctor in the room" as decoration. Boards hire clinical directors to reduce expensive mistakes: trial design, indication strategy, regulatory path, and whether a commercial story survives medical scrutiny. That is the same risk logic behind paid advisory retainers in What companies actually pay physicians for: What companies actually pay physicians for
Second, the biography is a portfolio of verifiable decisions. Named programmes, named roles, FDA committee service, prior boards. When a chair puts a name forward, other directors need a record they can check without a private tutorial. Thin public records transfer all the risk to the person making the introduction.That is why Board routes for clinicians stresses appointability over abstract qualification
Third, advisory and board work often sit on a continuum. Scott's history includes scientific and strategic advisory boards as well as corporate boards. Many practising physicians start with a healthtech advisory board or paid consulting lane, then become introducible for governance once the commercial judgement is visible. Jumping straight to a Nasdaq board without that trail is rare outside senior pharma CMO careers. Charity, trust and earlier-stage company seats remain the realistic first governance steps for most clinicians.
If you are a dermatologist or immunologist watching this news, the takeaway is not "copy AbbVie." Make the decision-types you already make legible: indication choices, safety signal reading, trial feasibility, payer medical policy, real-world use of topicals and biologics.
Who this is most relevant for
Dermatologists, immunologists and physicians adjacent to inflammatory disease who want board or advisory work. Physicians already in medical affairs, clinical development or diligence who want to translate that into governance. Clinicians earlier in the journey who need a realistic picture of senior board profiles so they can plan the first seat rather than chase the last one.
Governance appointments almost never start with a public application. They start with a named person who can already defend the choice.
What to do this week
Pick the governance lane that matches your experience: health technology, hospital or trust boards, charity and professional bodies, or investor advisory panels. Write that lane in one sentence on your profile.
Publish one piece of proof a non-clinician director could understand: a short article on a pipeline or adoption decision in your specialty, without patient detail and with interests disclosed.See Being visible without breaching anything
Ask two people who already sit on boards in your field for a coffee, not for a seat. Ask what they verified before the last clinician appointment. For a structured appointability plan, book a Power Hour or Meet.
Related: Moving into health technology without starting over and the insights blog.
Next step for physicians
If you want a public record that makes advisory, board and speaking invitations easier to earn, start with a Power Hour (60 minutes + 90-day plan) or book a short Meet conversation.Power Hour· Meet
